GE Healthcare Unveils CardioVisio: A Digital Clinical Decision Support Tool Enabling Precise Care for Atrial Fibrillation
Friday, August 25, 2023
GE Healthcare has launched CardioVisio for Atrial Fibrillation (AFib), a digital tool intended to aid clinicians in interpreting longitudinal data relevant to disease progression from multiple sources. The tool aims to provide evidence-based clinical decision support aligned with up-to-date AFib guidelines.
Cardiovascular diseases are a leading global cause of preventable, premature deaths. Among these, AFib is the most prevalent clinically diagnosed arrhythmia, affecting millions worldwide. However, AFib often goes misdiagnosed or undertreated, with potentially 30% of cases overlooked in routine clinical practice.
Developing precision care for AFib patients is crucial, as they face a fivefold higher risk of stroke and contribute significantly to hospitalizations. The current models for diagnosing and treating AFib have shown complexity, time inefficiency, and inconsistency with various guidelines, leading to inadequate adherence. CardioVisio for AFib provides cardiologists with a streamlined tool for image interpretation, offering insights into patients' cardiac history, healthcare journeys, prior diagnoses, prescribed medications, interventions, and comorbidities.
By visualizing longitudinal data from diverse sources, CardioVisio for AFib aims to simplify clinical decision-making, saving time and offering guideline-directed therapy recommendations. The automated steps are transparent and traceable, allowing healthcare providers to review and modify the process and outputs to better suit the unique needs of each AFib patient. The tool utilizes algorithms to process relevant data based on industry-published guidelines, potentially easing the burden of data overload and enabling timely, personalized, evidence-based care. Currently, CardioVisio for Atrial Fibrillation is available in the US, with plans to expand availability to incorporate additional regional guidelines in the coming months.